Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Tuberculosis

Free Subscription Articles published in J Antimicrob Chemother Retrieve available abstracts of 59 articles: HTML format Text format

Single Articles

March 2018
1. CANEZIN PH, Caleffi-Ferracioli KR, Scodro RBL, Siqueira VLD, et al
   Intramacrophage Mycobacterium tuberculosis efflux pump gene regulation after rifampicin and verapamil exposure.
   J Antimicrob Chemother. 2018 Mar 22. pii: 4951545. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   January 2018
2. DOOKIE N, Rambaran S, Padayatchi N, Mahomed S, et al
   Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.
   J Antimicrob Chemother. 2018 Jan 19. pii: 4817621. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   December 2017
3. LIU Y, Pertinez H, Ortega-Muro F, Alameda-Martin L, et al
   Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
   J Antimicrob Chemother. 2017 Dec 12. pii: 4735127. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   October 2017
4. VYAZOVAYA A, Levina K, Zhuravlev V, Viiklepp P, et al
   Emerging resistant clones of Mycobacterium tuberculosis in a spatiotemporal context.
   J Antimicrob Chemother. 2017 Oct 30. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
5. YEW WW, Liang D, Chan DP, Shi W, et al
   Molecular mechanisms of clofazimine resistance in Mycobacterium tuberculosis.
   J Antimicrob Chemother. 2017;72:2943-2944.
   PubMed     Text format    
   
   
   September 2017
6. CHEN J, Zhang S, Cui P, Shi W, et al
   Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis.
   J Antimicrob Chemother. 2017 Sep 12. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   August 2017
7. SVENSSON RJ, Gillespie SH, Simonsson USH
   Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods.
   J Antimicrob Chemother. 2017;72:2311-2319.
   PubMed     Text format     Abstract available
   
   
   June 2017
8. KAUSHIK A, Ammerman NC, Tasneen R, Story-Roller E, et al
   In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.
   J Antimicrob Chemother. 2017 Jun 1. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
9. YEW WW, Leung CC, Zhang Y
   Oxidative stress and TB outcomes in patients with diabetes mellitus?
   J Antimicrob Chemother. 2017;72:1552-1555.
   PubMed     Text format     Abstract available
   
   
   May 2017
10. MAITRE T, Petitjean G, Chauffour A, Bernard C, et al
    Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?
    J Antimicrob Chemother. 2017 May 23. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
11. NAIDOO A, Chirehwa M, McIlleron H, Naidoo K, et al
    Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
    J Antimicrob Chemother. 2017;72:1441-1449.
    PubMed     Text format     Abstract available
    
    
    April 2017
12. ZIMENKOV DV, Nosova EY, Kulagina EV, Antonova OV, et al
    Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
    J Antimicrob Chemother. 2017 Apr 6. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
13. SEKAGGYA-WILTSHIRE C, von Braun A, Scherrer AU, Manabe YC, et al
    Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
    J Antimicrob Chemother. 2017;72:1172-1177.
    PubMed     Text format     Abstract available
    
    
    March 2017
14. GURUMURTHY M, Verma R, Naftalin CM, Hee KH, et al
    Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial.
    J Antimicrob Chemother. 2017 Mar 18. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
15. JAGANATH D, Schaaf HS, Donald PR
    Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.
    J Antimicrob Chemother. 2017 Mar 9. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
16. VILLELLAS C, Coeck N, Meehan CJ, Lounis N, et al
    Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
    J Antimicrob Chemother. 2017;72:684-690.
    PubMed     Text format     Abstract available
    
    
    February 2017
17. CAVANAUGH JS, Jou R, Wu MH, Dalton T, et al
    Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
    J Antimicrob Chemother. 2017 Feb 20. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
18. CHOLO MC, Mothiba MT, Fourie B, Anderson R, et al
    Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.
    J Antimicrob Chemother. 2017;72:338-353.
    PubMed     Text format     Abstract available
    
    
    January 2017
19. GOTHAM D, Fortunak J, Pozniak A, Khoo S, et al
    Estimated generic prices for novel treatments for drug-resistant tuberculosis.
    J Antimicrob Chemother. 2017 Jan 10. pii: dkw522. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    December 2016
20. ROBERTSON GT, Scherman MS, Bruhn DF, Liu J, et al
    Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw467. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
21. NAGU TJ, Aboud S, Matee MI, Maeurer MJ, et al
    Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw503. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    October 2016
22. AMMERMAN NC, Swanson RV, Tapley A, Moodley C, et al
    Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available
    
    
    September 2016
23. HOFFMANN H, Borroni E, Schena E, Nedialkova L, et al
    Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system-authors' response.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    
    
    
    
24. BERNARD C, Aubry A, Chauffour A, Brossier F, et al
    In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available
    
    
    August 2016
25. IMKAMP F, Keller PM, Bottger EC
    Comment on: Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    
    
    
    June 2016
26. EILERTSON B, Maruri F, Blackman A, Guo Y, et al
    A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available
    
    
    
27. DUTTA NK, Bruiners N, Pinn ML, Zimmerman MD, et al
    Statin adjunctive therapy shortens the duration of TB treatment in mice.
    J Antimicrob Chemother. 2016;71:1570-7.
    PubMed     Text format     Abstract available
    
    
    May 2016
28. PANTEL A, Petrella S, Veziris N, Matrat S, et al
    Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available
    
    
    
29. HENNIG S, Svensson EM, Niebecker R, Fourie PB, et al
    Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.
    J Antimicrob Chemother. 2016;71:1330-40.
    PubMed     Text format     Abstract available
    
    
    
30. COJUTTI P, Duranti S, Isola M, Baraldo M, et al
    Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?
    J Antimicrob Chemother. 2016;71:1323-9.
    PubMed     Text format     Abstract available
    
    
    April 2016
31. SCHENA E, Nedialkova L, Borroni E, Battaglia S, et al
    Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available
    
    
    
32. PANDIE M, Wiesner L, McIlleron H, Hughes J, et al
    Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
    J Antimicrob Chemother. 2016;71:1037-40.
    PubMed     Text format     Abstract available
    
    
    
33. OLARU ID, Lange C, Heyckendorf J
    Personalized medicine for patients with MDR-TB.
    J Antimicrob Chemother. 2016;71:852-5.
    PubMed     Text format     Abstract available
    
    
    March 2016
34. SAKTIAWATI AM, Sturkenboom MG, Stienstra Y, Subronto YW, et al
    Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.
    J Antimicrob Chemother. 2016;71:703-10.
    PubMed     Text format     Abstract available
    
    
    
35. RIEU R, Chang C, Collin SM, Fazekas J, et al
    Time to detection in liquid culture of sputum in pulmonary MDR-TB does not predict culture conversion for early discharge.
    J Antimicrob Chemother. 2016;71:803-6.
    PubMed     Text format     Abstract available
    
    
    February 2016
36. ZIMENKOV DV, Kulagina EV, Antonova OV, Zhuravlev VY, et al
    Simultaneous drug resistance detection and genotyping of Mycobacterium tuberculosis using a low-density hydrogel microarray.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available
    
    
    
37. COECK N, de Jong BC, Diels M, de Rijk P, et al
    Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available
    
    
    
38. RIGOUTS L, Coeck N, Gumusboga M, de Rijk WB, et al
    Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.
    J Antimicrob Chemother. 2016;71:314-23.
    PubMed     Text format     Abstract available
    
    
    December 2015
39. CLEWE O, Aulin L, Hu Y, Coates AR, et al
    A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available
    
    
    
40. LOOTS DT
    New insights into the survival mechanisms of rifampicin-resistant Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available
    
    
    
41. LORTHOLARY O, Roussillon C, Boucherie C, Padoin C, et al
    Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available
    
    
    November 2015
42. NIWARD K, Angeby K, Chryssanthou E, Paues J, et al
    Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available
    
    
    
43. MEFTAHI N, Namouchi A, Mhenni B, Brandis G, et al
    Evidence for the critical role of a secondary site rpoB mutation in the compensatory evolution and successful transmission of an MDR tuberculosis outbreak strain.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available
    
    
    August 2015
44. JAGIELSKI T, Bakula Z, Roeske K, Kaminski M, et al
    Mutation profiling for detection of isoniazid resistance in Mycobacterium tuberculosis clinical isolates.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available
    
    
    
45. KNUDSON SE, Awasthi D, Kumar K, Carreau A, et al
    Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available
    
    
    July 2015
46. JEONG BH, Jeon K, Park HY, Kwon OJ, et al
    Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available
    
    
    
47. BAX HI, de Steenwinkel JE, Ten Kate MT, van der Meijden A, et al
    Colistin as a potentiator of anti-TB drug activity against Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available
    
    
    June 2015
48. ZHANG S, Chen J, Cui P, Shi W, et al
    Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available
    
    
    May 2015
49. TORREA G, Coeck N, Desmaretz C, Van De Parre T, et al
    Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available
    
    
    
50. MARTINEZ E, Holmes N, Jelfs P, Sintchenko V, et al
    Genome sequencing reveals novel deletions associated with secondary resistance to pyrazinamide in MDR Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available
    
    
    
51. HEINRICH N, Dawson R, du Bois J, Narunsky K, et al
    Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.
    J Antimicrob Chemother. 2015;70:1558-66.
    PubMed     Text format     Abstract available
    
    
    
52. KIM SH, Lee SO, Park IA, Kim SM, et al
    Isoniazid treatment to prevent TB in kidney and pancreas transplant recipients based on an interferon-gamma-releasing assay: an exploratory randomized controlled trial.
    J Antimicrob Chemother. 2015;70:1567-72.
    PubMed     Text format     Abstract available
    
    
    April 2015
53. HIRUY H, Rogers Z, Mbowane C, Adamson J, et al
    Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.
    J Antimicrob Chemother. 2015;70:1115-23.
    PubMed     Text format     Abstract available
    
    
    
54. OUTHRED AC, Jelfs P, Suliman B, Hill-Cawthorne GA, et al
    Added value of whole-genome sequencing for management of highly drug-resistant TB.
    J Antimicrob Chemother. 2015;70:1198-202.
    PubMed     Text format     Abstract available
    
    
    March 2015
55. CAMBAU E, Viveiros M, Machado D, Raskine L, et al
    Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study.
    J Antimicrob Chemother. 2015;70:686-96.
    PubMed     Text format     Abstract available
    
    
    February 2015
56. MOULTRIE H, McIlleron H, Sawry S, Kellermann T, et al
    Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.
    J Antimicrob Chemother. 2015;70:543-9.
    PubMed     Text format     Abstract available
    
    
    
57. HUANG Z, Qin C, Du J, Luo Q, et al
    Evaluation of the microscopic observation drug susceptibility assay for the rapid detection of MDR-TB and XDR-TB in China: a prospective multicentre study.
    J Antimicrob Chemother. 2015;70:456-62.
    PubMed     Text format     Abstract available
    
    
    
58. REYNOLDS HE, Chrdle A, Egan D, Chaponda M, et al
    Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir.
    J Antimicrob Chemother. 2015;70:550-4.
    PubMed     Text format     Abstract available
    
    
    April 2014
59. KALITA J, Misra UK, Prasad S, Bhoi SK, et al
    Safety and efficacy of levofloxacin versus rifampicin in tuberculous meningitis: an open-label randomized controlled trial.
    J Antimicrob Chemother. 2014.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: